Search Medical Condition
Please enter condition
Please choose location from dropdown

Codru, Moldova, Republic of Clinical Trials

A listing of Codru, Moldova, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (30) clinical trials

G1T38 a CDK 4/6 Inhibitor in Combination With Fulvestrant in Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer

This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study is an open-label design, consists of 2 parts: dose-finding portion (Part 1), and expansion portion (Part 2). Both parts ...

Phase

1.32 miles

Learn More »

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Subjects participating in this study with no clinically significant toxicities and no disease progression may be eligible to continue treatment on a separate extension protocol (MDV3800-13).

Phase

1.32 miles

Learn More »

Open-Label Extension and Safety Study of Talazoparib

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Phase

1.32 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval

Phase

1.32 miles

Learn More »

MabionCD20 Compared to MabThera in Lymphoma Patients

Patients who meet criteria for participation in this study receive 8 intravenous infusions of MabionCD20 or MabThera 21 days interval in combination with standard dosage regimen of CHOP. The duration of the study is 12 months. The treatment and observation period will last 26 weeks starting from Day 1, until ...

Phase

1.32 miles

Learn More »

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment

Phase

1.32 miles

Learn More »

PK PD Safety Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia

This is a two-part study intended to provide investigators and sponsor with the following information regarding the investigational new drug MT-3724: Part 1[COMPLETED]: in patients with relapsed/refractory non-Hodgkin's B cell lymphoma (including SLL) OR relapsed/refractory B-cell CLL The maximum dose of a single course of MT-3724 given as intravenous (IV) ...

Phase

1.32 miles

Learn More »

An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer

This is a multicenter, open-label study (participants will know the identity of study drugs administered) to evaluate the efficacy and safety of JNJ-42756493 in participants with urothelial cancer. The study comprises a 30-days Screening Phase, a Treatment Phase comprised of 28-day treatment cycles that will continue until disease progression or ...

Phase

1.32 miles

Learn More »

Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

The objective of this study is to evaluate the effect of multiple doses of vericiguat on the QTc interval in patients with stable CAD (coronary artery disease).

Phase

1.32 miles

Learn More »

An Efficacy Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

This is a multicenter, double-blind (neither physician nor participant knows the treatment that the participant receives), placebo-controlled, randomized, parallel-group study in participants with Major Depressive Disorder (MDD) with Anxious Distress. Participants who had treatment initiated with a SSRI/SNRI allowed by the protocol will be evaluated at the investigation site. The ...

Phase

1.32 miles

Learn More »